IDenta Corp. (IDTA)
USD 0.36
(0.0%)
USD 0.36
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1499.00 USD | -140.81% |
| 2022 | 125.48 Thousand USD | -41.41% |
| 2021 | 214.15 Thousand USD | -39.77% |
| 2020 | 355.57 Thousand USD | 246.07% |
| 2019 | 102.74 Thousand USD | -30.14% |
| 2018 | 147.06 Thousand USD | 197.48% |
| 2017 | -150.86 Thousand USD | 56.69% |
| 2016 | -348.31 Thousand USD | -0.24% |
| 2015 | -347.49 Thousand USD | 40.61% |
| 2014 | -585.08 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 64.67 Thousand USD | -58.79% |
| 2024 Q1 | 176.07 Thousand USD | 37.55% |
| 2023 FY | -51.21 Thousand USD | -140.81% |
| 2023 Q4 | 128 Thousand USD | 442.52% |
| 2023 Q3 | -37.37 Thousand USD | 51.05% |
| 2023 Q1 | -45.24 Thousand USD | -125.66% |
| 2023 Q2 | -76.35 Thousand USD | -68.76% |
| 2022 Q2 | 17.09 Thousand USD | 127.9% |
| 2022 FY | 125.48 Thousand USD | -41.41% |
| 2022 Q4 | 176.31 Thousand USD | 378.37% |
| 2022 Q3 | 36.85 Thousand USD | 115.6% |
| 2022 Q1 | -61.28 Thousand USD | -204.45% |
| 2021 Q3 | 1733.00 USD | -98.56% |
| 2021 Q2 | 119.99 Thousand USD | 62.47% |
| 2021 FY | 214.15 Thousand USD | -39.77% |
| 2021 Q4 | 58.67 Thousand USD | 3285.63% |
| 2021 Q1 | 73.85 Thousand USD | 199.94% |
| 2020 Q4 | -73.89 Thousand USD | -127.84% |
| 2020 FY | 355.57 Thousand USD | 246.07% |
| 2020 Q1 | 72.24 Thousand USD | 883.08% |
| 2020 Q2 | 101.59 Thousand USD | 40.62% |
| 2020 Q3 | 265.42 Thousand USD | 161.26% |
| 2019 Q3 | 59.01 Thousand USD | 34.79% |
| 2019 Q1 | 5944.00 USD | -88.41% |
| 2019 FY | 102.74 Thousand USD | -30.14% |
| 2019 Q4 | -9226.00 USD | -115.63% |
| 2019 Q2 | 43.78 Thousand USD | 636.57% |
| 2018 Q3 | 99.77 Thousand USD | 3100.83% |
| 2018 FY | 147.06 Thousand USD | 197.48% |
| 2018 Q4 | 51.29 Thousand USD | -48.59% |
| 2018 Q2 | 3117.00 USD | -76.03% |
| 2018 Q1 | 13 Thousand USD | 125.33% |
| 2017 FY | -150.86 Thousand USD | 56.69% |
| 2017 Q1 | -6825.00 USD | 0.0% |
| 2017 Q2 | -58.06 Thousand USD | -750.73% |
| 2017 Q3 | -50.22 Thousand USD | 13.49% |
| 2017 Q4 | -51.33 Thousand USD | -2.2% |
| 2016 FY | -348.31 Thousand USD | -0.24% |
| 2015 FY | -347.49 Thousand USD | 40.61% |
| 2014 FY | -585.08 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | 99.879% |
| Arrayit Corporation | -3.62 Million USD | 99.959% |
| Atlantic International Corp. | -5.73 Million USD | 99.974% |
| Biocept, Inc. | -31.98 Million USD | 99.995% |
| Bioqual, Inc. | -19.63 Thousand USD | 92.367% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | 99.806% |
| DermTech, Inc. | -103.73 Million USD | 99.999% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 100.0% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 99.993% |
| iMD Companies, Inc. | -175.44 Thousand USD | 99.146% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 100.053% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 103.874% |
| InVitro International | -25.33 Thousand USD | 94.084% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 99.979% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 97.42% |
| Medical Imaging Corp. | -819.48 Thousand USD | 99.817% |
| NovelStem International Corp. | -3.52 Million USD | 99.957% |
| Optigenex Inc. | 1.39 Million USD | 100.108% |
| PharmChem, Inc. | 973.14 Thousand USD | 100.154% |
| Proteome Sciences plc | -1.62 Million USD | 99.908% |
| Response Genetics, Inc | -21.37 Million USD | 99.993% |
| Rennova Health, Inc. | -1.4 Million USD | 99.894% |
| RushNet, Inc. | -684.7 Thousand USD | 99.781% |
| ScreenPro Security Inc. | -2.59 Million USD | 99.942% |
| Stella Diagnostics Inc. | -11.42 Million USD | 99.987% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 99.981% |
| Todos Medical Ltd. | -9.74 Million USD | 99.985% |